Exome Asset Management LLC: ENLIVEN THERAPEUTICS INC (ELVN): Quarterly 13F Position History
As of Q1 2026, Exome Asset Management LLC reported 220,091 shares of ENLIVEN THERAPEUTICS INC (ELVN), worth $8.6M and representing 5.1% of its 13F equity book. Quarter-over-quarter share count change: 2,217 (-1.0%) . The position first appeared in Q1 2024 and has been disclosed across 9 13F-HR filings in Pactolio's tracked window.
- 220,091Shares Held (Latest Filing)
- $8.6MReported Market Value (Latest Filing)
- 5.1%Portfolio Weight (% of 13F Equity Book)
- 2,217Quarter-over-Quarter Share Change
- +$5.2MQuarter-over-Quarter Value Change
- 222,308Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 9 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 220,091 | 2,217 | -1.0% | $8.6M | 5.1% | $39.2 |
| Q4 2025 | 222,308 | +222,308 | — | $3.4M | 1.7% | $15.4 |
| Q3 2025 | 0 | 0 | — | $0 | 0.0% | — |
| Q2 2025 | 0 | 0 | — | $0 | 0.0% | — |
| Q1 2025 | 0 | 0 | — | $0 | 0.0% | — |
| Q4 2024 | 0 | 0 | — | $0 | 0.0% | — |
| Q3 2024 | 0 | 0 | — | $0 | 0.0% | — |
| Q2 2024 | 0 | 57,635 | -100.0% | $0 | 0.0% | — |
| Q1 2024 | 57,635 | — | — | $1.0M | 0.9% | $17.6 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did Exome Asset Management LLC first disclose a ELVN position in 13F-HR filings?
Exome Asset Management LLC first reported ENLIVEN THERAPEUTICS INC (ELVN) on its 13F-HR filing for the period ending 2024-03-31 (Q1 2024). The position has appeared on 9 reported quarters within Pactolio's tracked window.
What was Exome Asset Management LLC's most recent quarter-over-quarter share-count change in ELVN?
Between Q4 2025 and Q1 2026, Exome Asset Management LLC reduced its ELVN position by 2,217 shares (-1.0%), leaving 220,091 shares at a market value of $8.6M.
Does the implied price-per-share represent Exome Asset Management LLC's cost basis in ELVN?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.